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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. 
Therefore, there is an urgent need to find appropriate strategies to afford cardioprotection. 
Cardiovascular health may be preserved and CVD can be fought with interventions aimed at 
protection, repair and regeneration of the heart. Despite great advances in treatment of patients with 
atherosclerosis and coronary heart disease, heart failure (HF) is still a huge problem. HF is a 
complex multifactorial syndrome, which may be caused by several clinical conditions, including 
coronary ischemic disease. It is often associated with one or more comorbidities and is 
characterized by several overlapping pathophysiological features. These include cardiac systolic 
and diastolic contractility abnormalities, occurrence of arrhythmias and organ hypoperfusion, as 
well as endothelial and vascular dysfunction, autonomic impairment, and neurohormonal 
imbalances. HF displays the greatest negative impact on the efficiency of a subject leading to the 
disruption of daily functioning and increasing dependence on caregivers. In particular, in our aging 
population, HF is a serious problem for the society, affecting the quality of life of millions of 
people. In view of the intolerable burden required to the society, there is an urgent need to develop 
new treatments to reduce the toll from coronary heart disease and HF and to improve the life quality 
of individuals. To achieve this goal, new and effective therapeutic approaches are required, but to 
achieve the latter multidisciplinary approaches are required that aim at defining the signaling 
mechanisms and molecular interactions that address myocardial tissue towards a cardio- vascular 
protective phenotype [1]. In this special issue “Protection, Repair and Regeneration of Achybreaky 
Heart”, we highlight the known mechanisms leading to heart disease, discuss current approaches 
and future therapeutic strategies for targeting a damaged heart. The role of epigenetic, genomic, 
proteomic, and metabolomic systems biology approaches to uncover novel strategies for targeting 
mechanisms of myocardial damage are addressed in the context of several cardiovascular disease 
and in particular in the context of ischemia/reperfusion injury and atherosclerosis. Together, the 
review articles in this issue highlight the critical need for advancements in developing therapeutics 
strategies targeted at the cardiovascular system that will be effectively translated to the clinic to 
significantly impact CVD treatment. In particular, in their review, Urbanek et al. [2] discuss the role 
of resident and extracardiac progenitors in the pathogenesis of cardiomyopathies of different 
etiology for both a better understanding of cardiac homeostasis and to pave the way for new 
therapeutic approaches. The authors propose new strategies for the exploitation of the potential for 
self-renewal myocardial and systemic cardiogenic cells. Madonna et al. [3] discuss the genes and 
signaling pathways that play a crucial role in the aging of stem cells, reporting ex vivo approaches 
that consider genetic modification as a tool to rejuvenate stem cells. They also discuss innovative 
approaches to improve the cellular retention of interest for the cardiovascular system. Moreover, 
Matteucci et al. [4] discuss how the cardiovascular microenvironment exposed to various stressors 
can trigger epigenetic changes that affect the function, proliferation, survival, and senescence of all 
cardiac cells. Moccia et al. [5], analyze how intracellular Ca2+ signal can be targeted to redirect 
stem cell toward lineages able to restore cardiac vascularization and contractility. In their review, 
Varga et al. [6], propose a comprehensive analysis of gene expression fingerprint in normal, 
protected, and in comorbidity conditions and propose that this analysis may lead to identification of 
novel molecular targets for cardioprotection. Several, endogenous factors, signaling pathways and 
possible targets involved in cardioprotection (preconditioning, perconditioning and 
postconditioning) are discussed by Penna et al. [7], whereas Weber et al. [8] discuss the 
cardioprotective signaling pathway and targets of the non-anesthetic noble gas helium. From these 
articles, the fundamental role played by the nitroso-redox balance in determining CVD and 
cardioprotection is evident. In their review, Tocchetti et al. [9], focus on the crucial role of nitroso-
redox balance in cardiac function. Given the central role of mitochondria in cardioprotection, the 
processes of mitochondrial fusion and fission are attracting the attention of many researchers. In 
this issue, the role of mitochondrial fusion protein optic atrophy protein 1 in cardiovascular health 
and disease is analyzed by Burke et al. [10]. These authors also explore the role of this protein as a 
potential therapeutic target for treating CVD. Deniset and Pierce [11] focus their attention on heat 
shock proteins in CVD and, in particular, in atherosclerotic vascular disease, and discuss the 
therapeutic potential to target these proteins to affect the natural progression of CVD. The emerging 
role of Nefastin-1 in affecting several cardiac functions in health and disease is discussed by 
Imbrogno et al. [12]. Finally, the role of hyperpolarization-activated cyclic nucleotide-gated 
channels in the progression of cardiac diseases, rhythm disturbances and their targeting by novel 
drugs to treat several conditions is discussed by Sartiani et al. [13]. Altogether, these reviews can 
open the way for studies aimed at identifying new selective compounds with greater selectivity as 
potential candidates for drug development. We hope that studies stimulated by this special issue, by 
exploring more efficient and protective signaling pathways and cell therapies for the improvement 
of heart function, will expand the current list of treatments and options to prevent or revert 
cardiomyopathies. Editorial Current Drug Targets, 2015, Vol. 16, No. 8 779 
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